Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
作者： Jolien Tol , Miriam Koopman , Annemieke Cats , Cees J. Rodenburg , Geert J.M. Creemers
关键词:
摘要: Background Fluoropyrimidine-based chemotherapy plus the anti–vascular endothelial growth factor (VEGF) antibody bevacizumab is standard first-line treatment for metastatic colorectal cancer. We studied effect of adding anti–epidermal receptor (EGFR) cetuximab to a combination capecitabine, oxaliplatin, and Methods randomly assigned 755 patients with previously untreated cancer (CB regimen, 378 patients) or same regimen weekly (CBC 377 patients). The primary end point was progression-free survival. mutation status KRAS gene evaluated as predictor outcome. Results median survival 10.7 months in CB group 9.4 CBC (P=0.01). Quality-of-life scores were lower group. overall response rates did not differ significantly two groups. Treated ...
ru.nl
narcis.nl
uva.nl 
researchgate.net 参考文章(25)
R M Shaheen, S A Ahmad, W Liu, N Reinmuth, Y D Jung, W W Tseng, K E Drazan, C D Bucana, D J Hicklin, L M Ellis, Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors British Journal of Cancer. ,vol. 85, pp. 584- 589 ,(2001) , 10.1054/BJOC.2001.1936
C. Bokemeyer, I. Bondarenko, J. T. Hartmann, F. G. De Braud, C. Volovat, J. Nippgen, C. Stroh, I. Celik, P. Koralewski, KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience Journal of Clinical Oncology. ,vol. 26, pp. 4000- 4000 ,(2008) , 10.1200/JCO.2008.26.15_SUPPL.4000
Rainer Porschen, Hendrik-Tobias Arkenau, Stephan Kubicka, Richard Greil, Thomas Seufferlein, Werner Freier, Albrecht Kretzschmar, Ullrich Graeven, Axel Grothey, Axel Hinke, Wolff Schmiegel, Hans-Joachim Schmoll, Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Leucovorin Plus Oxaliplatin in Metastatic Colorectal Cancer: A Final Report of the AIO Colorectal Study Group Journal of Clinical Oncology. ,vol. 25, pp. 4217- 4223 ,(2007) , 10.1200/JCO.2006.09.2684
Tait D. Shanafelt, Curtis Hanson, Gordon W. Dewald, Thomas E. Witzig, Betsy LaPlant, Jennifer Abrahamzon, Diane F. Jelinek, Neil E. Kay, Karyotype Evolution on Fluorescent In Situ Hybridization Analysis Is Associated With Short Survival in Patients With Chronic Lymphocytic Leukemia and Is Related to CD49d Expression Journal of Clinical Oncology. ,vol. 26, ,(2008) , 10.1200/JCO.2008.16.7874
C. Bokemeyer, E. Staroslawska, A. Makhson, I. Bondarenko, J.T. Hartmann, Y. Shelygin, O. Kolesnik, C. Volovat, A. Zubel, P. Koralewski, 3004 ORAL Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) in the first-line treatment of metastastic colorectal cancer (mCRC): a large-scale phase II study, OPUS Ejc Supplements. ,vol. 5, pp. 236- ,(2007) , 10.1016/S1359-6349(07)70932-1
Y.D. Jung, P.F. Mansfield, M. Akagi, A. Takeda, W. Liu, C.D. Bucana, D.J. Hicklin, L.M. Ellis, Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model. European Journal of Cancer. ,vol. 38, pp. 1133- 1140 ,(2002) , 10.1016/S0959-8049(02)00013-8
Fairooz F. Kabbinavar, Julie Hambleton, Robert D. Mass, Herbert I. Hurwitz, Emily Bergsland, Somnath Sarkar, Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer Journal of Clinical Oncology. ,vol. 23, pp. 3706- 3712 ,(2005) , 10.1200/JCO.2005.00.232
W. De Roock, H. Piessevaux, J. De Schutter, M. Janssens, G. De Hertogh, N. Personeni, B. Biesmans, J.-L. Van Laethem, M. Peeters, Y. Humblet, E. Van Cutsem, S. Tejpar, KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab Annals of Oncology. ,vol. 19, pp. 508- 515 ,(2008) , 10.1093/ANNONC/MDM496
James R. Tonra, Dhanvanthri S. Deevi, Erik Corcoran, Huiling Li, Su Wang, Francine E. Carrick, Daniel J. Hicklin, Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy. Clinical Cancer Research. ,vol. 12, pp. 2197- 2207 ,(2006) , 10.1158/1078-0432.CCR-05-1682
Matthew T Seymour, Timothy S Maughan, Jonathan A Ledermann, Clare Topham, Roger James, Stephen J Gwyther, David B Smith, Stephen Shepherd, Anthony Maraveyas, David R Ferry, Angela M Meade, Lindsay Thompson, Gareth O Griffiths, Mahesh KB Parmar, Richard J Stephens, Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. The Lancet. ,vol. 370, pp. 143- 152 ,(2007) , 10.1016/S0140-6736(07)61087-3